Valeant Pharmaceuticals International has signed a binding agreement to acquire a private branded generics and OTC company located in Brazil for approximately $28 million. Much of the unnamed company’s product portfolio is in dermatology; it had annual sales of approximately $19 million in 2009. Also, Valeant will acquire a new 165,000-sq.-ft. manufacturing plant in Sao Paolo, approved to produce solids, semi-solids and liquids for approximately $28 million. Both transactions, which are...